206 related articles for article (PubMed ID: 16219634)
1. Meloxicam inhibits osteosarcoma growth, invasiveness and metastasis by COX-2-dependent and independent routes.
Naruse T; Nishida Y; Hosono K; Ishiguro N
Carcinogenesis; 2006 Mar; 27(3):584-92. PubMed ID: 16219634
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of meloxicam and conventional cytotoxic drugs in human MG-63 osteosarcoma cells.
Naruse T; Nishida Y; Ishiguro N
Biomed Pharmacother; 2007 Jul; 61(6):338-46. PubMed ID: 17395421
[TBL] [Abstract][Full Text] [Related]
3. Specific COX-2 inhibitor, meloxicam, suppresses proliferation and induces apoptosis in human HepG2 hepatocellular carcinoma cells.
Li J; Chen X; Dong X; Xu Z; Jiang H; Sun X
J Gastroenterol Hepatol; 2006 Dec; 21(12):1814-20. PubMed ID: 17074019
[TBL] [Abstract][Full Text] [Related]
4. Antineoplastic effect of the cyclooxygenase inhibitor meloxicam on canine osteosarcoma cells.
Wolfesberger B; Walter I; Hoelzl C; Thalhammer JG; Egerbacher M
Res Vet Sci; 2006 Jun; 80(3):308-16. PubMed ID: 16182328
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of meloxicam, a selective cyclooxygenase-2 inhibitor, and ciglitazone, a peroxisome proliferator-activated receptor gamma ligand, on the growth of human ovarian cancers.
Xin B; Yokoyama Y; Shigeto T; Futagami M; Mizunuma H
Cancer; 2007 Aug; 110(4):791-800. PubMed ID: 17582802
[TBL] [Abstract][Full Text] [Related]
6. Meloxicam inhibits the growth of non-small cell lung cancer.
Tsubouchi Y; Mukai S; Kawahito Y; Yamada R; Kohno M; Inoue K; Sano H
Anticancer Res; 2000; 20(5A):2867-72. PubMed ID: 11062695
[TBL] [Abstract][Full Text] [Related]
7. Meloxicam suppresses hepatocellular carcinoma cell proliferation and migration by targeting COX-2/PGE2-regulated activation of the β-catenin signaling pathway.
Li T; Zhong J; Dong X; Xiu P; Wang F; Wei H; Wang X; Xu Z; Liu F; Sun X; Li J
Oncol Rep; 2016 Jun; 35(6):3614-22. PubMed ID: 27109804
[TBL] [Abstract][Full Text] [Related]
8. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and -independent pathways.
Dong X; Li R; Xiu P; Dong X; Xu Z; Zhai B; Liu F; Jiang H; Sun X; Li J; Qiao H
PLoS One; 2014; 9(3):e92864. PubMed ID: 24675684
[TBL] [Abstract][Full Text] [Related]
9. Proapoptotic and antiproliferative potential of selective cyclooxygenase-2 inhibitors in human liver tumor cells.
Kern MA; Schubert D; Sahi D; Schöneweiss MM; Moll I; Haugg AM; Dienes HP; Breuhahn K; Schirmacher P
Hepatology; 2002 Oct; 36(4 Pt 1):885-94. PubMed ID: 12297835
[TBL] [Abstract][Full Text] [Related]
10. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo.
Liu JF; Zhang SW; Jamieson GG; Zhu GJ; Wu TC; Zhu TN; Shan BE; Drew PA
Int J Cancer; 2008 Apr; 122(7):1639-44. PubMed ID: 18058818
[TBL] [Abstract][Full Text] [Related]
11. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
[TBL] [Abstract][Full Text] [Related]
12. Metformin synergistically enhances antitumor activity of histone deacetylase inhibitor trichostatin a against osteosarcoma cell line.
Duo J; Ma Y; Wang G; Han X; Zhang C
DNA Cell Biol; 2013 Apr; 32(4):156-64. PubMed ID: 23451817
[TBL] [Abstract][Full Text] [Related]
13. Meloxicam inhibits the growth of colorectal cancer cells.
Goldman AP; Williams CS; Sheng H; Lamps LW; Williams VP; Pairet M; Morrow JD; DuBois RN
Carcinogenesis; 1998 Dec; 19(12):2195-9. PubMed ID: 9886578
[TBL] [Abstract][Full Text] [Related]
14. Etodolac inhibits EBER expression and induces Bcl-2-regulated apoptosis in Burkitt's lymphoma cells.
Kobayashi M; Nakamura S; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Ohnishi K
Eur J Haematol; 2005 Sep; 75(3):212-20. PubMed ID: 16104877
[TBL] [Abstract][Full Text] [Related]
15. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Pajdo R; Drozdowicz D; Ptak A; Hahn EG
Microsc Res Tech; 2001 Jun; 53(5):343-53. PubMed ID: 11376495
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of nonsteroidal anti-inflammatory drugs on cyclooxygenase activity in dogs.
Kay-Mugford P; Benn SJ; LaMarre J; Conlon P
Am J Vet Res; 2000 Jul; 61(7):802-10. PubMed ID: 10895904
[TBL] [Abstract][Full Text] [Related]
17. The in vitro effects of piroxicam and meloxicam on canine cell lines.
Knottenbelt C; Chambers G; Gault E; Argyle DJ
J Small Anim Pract; 2006 Jan; 47(1):14-20. PubMed ID: 16417605
[TBL] [Abstract][Full Text] [Related]
18. COX inhibitors modulate bFGF-induced cell survival in MCF-7 breast cancer cells.
Teh SH; Hill AK; Foley DA; McDermott EW; O'Higgins NJ; Young LS
J Cell Biochem; 2004 Mar; 91(4):796-807. PubMed ID: 14991771
[TBL] [Abstract][Full Text] [Related]
19. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
20. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
Puhlmann U; Ziemann C; Ruedell G; Vorwerk H; Schaefer D; Langebrake C; Schuermann P; Creutzig U; Reinhardt D
J Pharmacol Exp Ther; 2005 Jan; 312(1):346-54. PubMed ID: 15501994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
